Immunizing against Anogenital Cancer: HPV Vaccines

被引：28

作者：

Pogoda, Cloe S. ^{[1
]}

Roden, Richard B. S. ^{[2
]}

Garcea, Robert L. ^{[1
]}

机构：

[1] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA

[2] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA

来源：

PLOS PATHOGENS | 2016年 / 12卷 / 05期

关键词：

HUMAN-PAPILLOMAVIRUS; IMMUNOGENICITY; NEUTRALIZATION; TRIAL; WOMEN;

D O I：

10.1371/journal.ppat.1005587

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

[No abstract available]

引用

页数：5

共 20 条

[1] The causal relation between human papillomavirus and cervical cancer [J].

Bosch, FX ;

Lorincz, A ;

Muñoz, N ;

Meijer, CJLM ;

Shah, KV .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265

[2] Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions [J].

Chen, Jiezhong ;

Ni, Guoying ;

Liu, Xiao Song .

CELLULAR IMMUNOLOGY, 2011, 269 (01) :5-9

[3] Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States [J].

Chesson, Harrell W. ;

Ekwueme, Donatus U. ;

Saraiya, Mona ;

Watson, Meg ;

Lowy, Douglas R. ;

Markowitz, Lauri E. .

VACCINE, 2012, 30 (42) :6016-6019

[4]

de Sanjose S, HUMAN PAPILLOMAVIRUS

[5] Long-term efficacy and safety of human papillomavirus vaccination [J].

De Vincenzo, Rosa ;

Conte, Carmine ;

Ricci, Caterina ;

Scambia, Giovanni ;

Capelli, Giovanni .

INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2014, 6 :999-1010

[6] Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial [J].

Dobson, Simon R. M. ;

McNeil, Shelly ;

Dionne, Marc ;

Dawar, Meena ;

Ogilvie, Gina ;

Krajden, Mel ;

Sauvageau, Chantal ;

Scheifele, David W. ;

Kollmann, Tobias R. ;

Halperin, Scott A. ;

Langley, Joanne M. ;

Bettinger, Julie A. ;

Singer, Joel ;

Money, Deborah ;

Miller, Dianne ;

Naus, Monika ;

Marra, Fawziah ;

Young, Eric .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (17) :1793-1802

[7] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years [J].

Einstein, Mark H. ;

Baron, Mira ;

Levin, Myron J. ;

Chatterjee, Archana ;

Fox, Bradley ;

Scholar, Sofia ;

Rosen, Jeffrey ;

Chakhtoura, Nahida ;

Meric, Dorothee ;

Dessy, Francis J. ;

Datta, Sanjoy K. ;

Descamps, Dominique ;

Dubin, Gary .

HUMAN VACCINES, 2011, 7 (12) :1343-1358

[8] Development of a highly thermostable, adjuvanted human papillomavirus vaccine [J].

Hassett, Kimberly J. ;

Meinerz, Natalie M. ;

Semmelmann, Florian ;

Cousins, Megan C. ;

Garcea, Robert L. ;

Randolph, Theodore W. .

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 94 :220-228

[9] Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines [J].

Jagu, Subhashini ;

Karanam, Balasubramanyam ;

Gambhira, Ratish ;

Chivukula, Sudha V. ;

Chaganti, Revathi J. ;

Lowy, Douglas R. ;

Schiller, John T. ;

Roden, Richard B. S. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (11) :782-792

[10] Therapeutic Vaccine Strategies against Human Papillomavirus [J].

Khallouf, Hadeel ;

Grabowska, Agnieszka K. ;

Riemer, Angelika B. .

VACCINES, 2014, 2 (02) :422-462

← 1 2 →